Table 3 |
|||||
|
Comparison of 2-year radiographic progression among tumor necrosis factor antagonists |
|||||
|
Baseline characteristics |
Radiographic progression results |
||||
|
|
|
||||
|
Cohort |
Numbera |
Disease duration, yearsb |
mSASSS valueb |
Mean mSASSS change from baseline to year 2b |
Between-cohort P value |
|
|
|||||
|
Etanercept [2] |
257 |
10 ± 8.5 |
16 ± 18.3 |
0.9 ± 2.5 |
0.996 |
|
OASIS |
175 |
11 ± 8.5 |
14 ± 17.6 |
1.0 ± 3.2 |
|
|
Infliximab [3] |
156 |
10.2 ± 8.7 |
17.7 ± 17.9 |
0.9 ± 2.6 |
0.541 |
|
OASIS |
165 |
11.3 ± 8.6 |
15.8 ± 18.1 |
1.0 ± 3.2 |
|
|
Adalimumab |
307 |
11.2 ± 9.3 |
19.8 ± 19.3 |
0.8 ± 2.6 |
0.771 |
|
OASIS |
169 |
11.3 ± 8.6 |
15.8 ± 17.6 |
0.9 ± 3.3 |
|
|
|
|||||
|
aNumber of patients with a baseline and a year-2 radiograph. bValues are mean ± standard deviation. mSASSS, modified Stoke Ankylosing Spondylitis Spinal Score; OASIS, Outcome in Ankylosing Spondylitis International Study. |
|||||
|
van der Heijde et al. Arthritis Research & Therapy 2009 11:R127 doi:10.1186/ar2794 |
|||||
